Provided is a composition for enhancing effects of an anticancer agent using an oriental medicine, jaeumganghwa-tang, bojungikgi-tang, or yukmijihwang-tang. More particularly, provided is a composition for treating a neoplastic disease by administering an anticancer agent into an individual, and administering an oriental medicine into the individual within 30 minutes. The composition remarkably reduces side effects occurring when the anticancer agent is administered alone by co-administration of the oriental medicine, reduces cytotoxicity, and has higher anticancer activity than that when the anticancer agent is administered alone.

The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax ginseng-Red, Atractylodes rhizoma-White, Massa medicata fermentata, Citrus reticulata-Viride, Citrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructus-Red, and Zingiber officinale radix.

The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax ginseng-Red, Atractylodes rhizoma-White, Massa medicata fermentata, Citrus reticulata-Viride, Citrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructus-Red, and Zingiber officinale radix.

The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax ginseng-Red, Atractylodes rhizoma-White, Massa medicata fermentata, Citrus reticulata-Viride, Citrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructus-Red, and Zingiber officinale radix.

Provided are an antithrombotic composition (platelet aggregation inhibitor) comprising an Angelica gigas Nakai extract and a pharmaceutical composition for prevention and/or treatment of vascular disease, which comprises an Angelica gigas Nakai extract. The compositions are characterized in that they do not cause a gastrointestinal disorder.

Provided are an antithrombotic composition (platelet aggregation inhibitor) comprising an Angelica gigas Nakai extract and a pharmaceutical composition for prevention and/or treatment of vascular disease, which comprises an Angelica gigas Nakai extract. The compositions are characterized in that they do not cause a gastrointestinal disorder.

An agent for modulating expression of a heat shock protein gene, comprising a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. Also described are compositions comprising the same, as well as methods of making and using such agents and compositions.

An agent for modulating expression of a heat shock protein gene, comprising a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. Also described are compositions comprising the same, as well as methods of making and using such agents and compositions.

A low glycemic gummy composition is provided. The gummy composition includes a gelling component in a sufficient amount to provide a cohesive gelled product, and a low glycemic index sugar component having a glycemic index of not more than 20. The gummy composition includes not less than 50% weight of the low glycemic index sugar component. In some embodiments, the gummy composition further includes an active component, wherein the active component comprises a vitamin composition, a mineral composition, an amino acid composition, an antioxidant composition, an herbal composition, or an active pharmaceutical ingredient (API) composition. The gummy composition may be substantially free of D-glucose, D-fructose, and sugar substitutes such as non-sugar sweeteners and sugar alcohols.

A low glycemic gummy composition is provided. The gummy composition includes a gelling component in a sufficient amount to provide a cohesive gelled product, and a low glycemic index sugar component having a glycemic index of not more than 20. The gummy composition includes not less than 50% weight of the low glycemic index sugar component. In some embodiments, the gummy composition further includes an active component, wherein the active component comprises a vitamin composition, a mineral composition, an amino acid composition, an antioxidant composition, an herbal composition, or an active pharmaceutical ingredient (API) composition. The gummy composition may be substantially free of D-glucose, D-fructose, and sugar substitutes such as non-sugar sweeteners and sugar alcohols.